ZASTOSOWANIE METOD ANALITYCZNYCH W OZNACZANIU AKTYWNOŚCI DEHYDROGENAZY INOZYNOMONOFOSFORANOWEJ (IMPDH) PODCZAS TERAPII IMMUNOSUPRESYJNEJ

Arkadiusz Kocur; Dorota Marszałek; Tomasz Pawiński

doi:10.56782/pps.13

Published : 2020-08-07

Vol. 18 No. 5 (2020)

USE OF CHROMATOGRAPHIC METHODS FOR INOSINE DEHYDROGENASE ACTIVITY DETERMINATION (IMPDH) IN IMMUNOSUPPRESSIVE THERAPY

Arkadiusz Kocur

Dorota Marszałek

Tomasz Pawiński

DOI: https://doi.org/10.56782/pps.13

Abstract

Inosine-5′-monophosphate dehydrogenase (IMPDH) plays a key role in the de novo pathway synthesis and metabolism of the purine nucleotides, especially in the B and T lymphocyte cells. There are two isoforms of this enzyme (IMPDH I and IMPDH II) encoded by different genes, located on two different chromosomes. The IMPDH II isoform is dominant over the IMPDH I in rapidly proliferating lymphocytic cells. For that reason, the clinical significance of IMPDH is most important according to the immunosuppressive and anticancer therapy. The widely used immunosuppressant agents in post-transplantation therapy are mycophenolates (morpholinoethyl ester of mycophenolic acid and mycophenolate sodium) which are strong, non-competitive and reversible inhibitors of IMPDH. It should be noted that concentration of that agents must be monitored in the blood, due to narrow therapeutic range. The following literature review presents methods which may be used in determination of IMPDH activity and should be associated with the PK/PD (pharmacokinetic-pharmacodynamic) models. The work compares the methods developed over the last 25 years in terms of their usefulness and speed of performance for the determination in diagnostic laboratory. Special attention has been paid using chromatographic methods due to its specificity and recognizing it as “gold standard” in measurment of IMPDH activity as biomarkers.

Keywords:

IMPDH, HPLC, immunosuppressive therapy, mycophenolic acid, PK/PD-model

Most read articles by the same author(s)

Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
Bartłomiej Kot, Mateusz Moczulski, Agnieszka Czajkowska, Arkadiusz Kocur, Pharmacotherapy of apnea in the premature neonatological subpopulation – therapeutic opportunities, pharmacokinetic implications and recommendations for therapeutic drug monitoring , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)

Similar Articles

Karolina Księżarczyk, Bartłomiej Sankowski, SELECTED ASPECTS OF PARENTERAL NUTRITION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 4 (2017)
Kinga Grużewska-Piotrowska, Agnieszka Grużewska, Medication overuse headache as a consequence of taking painkillers – a review of current literature , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Aleksandra Grzybowska, Tomasz Lorenc, Wioletta Olejarz, Grażyna Nowicka, EXOSOMES AS CARRIERS OF INFORMATION BEETWEN TUMOR CELLS , Prospects in Pharmaceutical Sciences: Vol. 17 No. 2 (2019)
Aneta Emilia Jabłońska, Krzysztof Adam Stępień, COUNTERFEITING OF MEDICINAL PRODUCTS AND THREATS ASSOCIATED WITH THEIR TAKING , Prospects in Pharmaceutical Sciences: Vol. 17 No. 11 (2019)
Paulina Wilczyńska, Barbara Lisowska-Myjak, ROLA AMINOPEPTYDAZ ŁOŻYSKOWYCH W PRZEBIEGU CIĄŻY , Prospects in Pharmaceutical Sciences: Vol. 17 No. 1 (2019)
Martyna Chechłacz, Natalia Korytowska, COMPOUNDS THAT BIND TO PLASMA PROTEINS IN HUMANS. SIGNIFICANCE IN THERAPY AND METHODS FOR QUANTIFICATION OF A FREE FRACTION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 6 (2017)
Jadwiga Turło, FUNGAL BIOTECHNOLOGY. APPLICATIONS IN PHARMACY AND SUPPLEMENTATION , Prospects in Pharmaceutical Sciences: Vol. 11 No. 3 (2013)
Grzegorz Nałęcz-Jawecki, Tomasz Zawadzki, Agata Skrzypczak, SUNSCREENS AND THE ENVIROMENT , Prospects in Pharmaceutical Sciences: Vol. 10 No. 5 (2012)
Agnieszka Lis-Cieplak, ADAMANTANE DERIVATIVES - VARIETY OF BIOLOGICAL ACTIVITIES. A REVIEW OF MEDICATIONS APPROVED IN POLAND AND POTENTIAL DRUGS , Prospects in Pharmaceutical Sciences: Vol. 10 No. 3 (2012)
Dominika Winiarz, Kamila Domańska, Kinga Paluch, Dorota Dorota Skrajnowska, PROBIOTICS AND HEALTH - TODAY AND TOMORROW , Prospects in Pharmaceutical Sciences: Vol. 15 No. 10 (2017)

<< < 1 2 3 4 5 6 7 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Kocur, A., Marszałek, D., & Pawiński, T. (2020). USE OF CHROMATOGRAPHIC METHODS FOR INOSINE DEHYDROGENASE ACTIVITY DETERMINATION (IMPDH) IN IMMUNOSUPPRESSIVE THERAPY. Prospects in Pharmaceutical Sciences, 18(5), 40–49. https://doi.org/10.56782/pps.13

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Sollinger H.W.: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients- U.S. Renal Transplant Mycophenolate Mofetil Study Group, Transplantation, 1995, 60(3): 225-232. DOI: https://doi.org/10.1097/00007890-199508000-00003

Allison A. C., Elsie M.E.: Mycophenolate mofetil and its mechanisms of action, Immunopharmacology, 2000, 47.2-3: 85-118. DOI: https://doi.org/10.1016/S0162-3109(00)00188-0

Hedstrom L.: IMP dehydrogenase: structure, mechanism, and inhibition, Chemical Reviews, 2009, 109(7): 2903-28. DOI: https://doi.org/10.1021/cr900021w

Jain J., Almquist S. J., Ford P. J., Shlyakhter D., Wang Y., Nimmesgern E., Germann U.: Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human

lymphocytes. Biochemical Pharmacology, 2004, 67(4): 767-776. DOI: https://doi.org/10.1016/j.bcp.2003.09.043

Sombogaard F., Peeters A. M., Baan C. C., Mathot R. A., Quaedackers M. E., Vulto A. G., Weimar W., van Gelder T.: Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not, Therapeutic Drug Monitoring, 2009, 31(5): 549–556.

Budde K., Glander P., Bauer S., Braun K., Waiser J., Fritsche L., Neumayer, H. H.: Pharmacodynamic monitoring of mycophenolate mofetil. Clinical Chemistry and Medicine Laboratory, 2000, 38(11): 1213-1216. DOI: https://doi.org/10.1515/CCLM.2000.191

Carr S. F., Papp E., Wu J. C., Natsumeda, Y.: Characterization of human type I and type II IMP dehydrogenases, Journal of Biological Chemistry, 1993, 268(36): 27286-27290. DOI: https://doi.org/10.1016/S0021-9258(19)74247-1

Oellerich M., Barten M. J., Armstrong V. W.: Biomarkers- The Link Between Therapeutic Drug Monitoring and Pharmacodynamics, Therapeutic Drug Monitoring, 2006, 28:35-38. DOI: https://doi.org/10.1097/01.ftd.0000194503.85763.f5

Kellum J. A., Lameire N., Aspelin P., Barsoum R. S., Burdmann E. A., Goldstein S. L., Herzog C. A., Joannidis M., Kribben A., Levey A. S., MacLeod A. M., Mehta R. L., Murray P. T., Naicker S., Opal S. M., Schaefer F., Schetz M., Uchino S.: Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury, Kidney International Supplements, 2012, 2(1): 1-138.

Raggi M. C., Siebert S. B., Steimer W.: Customized Mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients’ outcomes after renal transplantation, Transplantation, 2010, 90: 1536-1541. DOI: https://doi.org/10.1097/TP.0b013e3182000027

Magasanik B., Moyed H. S., Gehring L. B.: B.: Enzymes essential for the biosynthesis of nucleic acid guanine- inosine 5'-phosphate dehydrogenase of Aerobacter aerogenes, Journal of Biological Chemistry, 1957, 226(1): 339-350. DOI: https://doi.org/10.1016/S0021-9258(18)64835-5

Proffitt R. T., Pathak V. K., Villacorte D. G., Presant, C. A.: Sensitive radiochemical assay for inosine 5′-monophosphate dehydrogenase and determination of activity in murine tumor and tissue extracts, Cancer Research, 1983, 43(4): 1620-1623.

Ikegami T., Natsumeda Y., Weber G.: Direct assay method for inosine 5′-monophosphate dehydrogenase activity, Analytical biochemistry, 1985, 150(1): 155-160. DOI: https://doi.org/10.1016/0003-2697(85)90454-3

Balzarini J., De Clercq E.: Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes, Biochemical Journal, 1992, 287(3): 785-790. DOI: https://doi.org/10.1042/bj2870785

Shimura K., Okada M., Shiraki H., Nakagawa H.: IMP dehydrogenaseStudies on regulatory properties of crude tissue extracts based on an improved assay method, The Journal of Biochemistry, 1983, 94(5:): 1595-1603.

Montero C., Duley J. A., Fairbanks L. D., McBride M. B., Micheli V., Cant A. J., Morgan G.: Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high-performance liquid chromatography linked method, Clinica Chimica Acta, 1995, 238(2): 169-178. DOI: https://doi.org/10.1016/0009-8981(95)06088-U

Vethe N. T., Bremer S., Rootwelt H., Bergan S.: Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Therapeutic Drug Monitoring, 2008, 30(6): 647-655. DOI: https://doi.org/10.1097/FTD.0b013e31818955c3

Vethe N. T., Ali A. M., Reine P. A., Andersen A. M., Bremer S., Line P. D., Bergan S.: Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid. Therapeutic Drug Monitoring, 2014, 36(1): 108-118. DOI: https://doi.org/10.1097/FTD.0b013e3182a13900

Albrecht W., Storck M., Pfetsch E., Martin W., Abendroth D.: Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5´-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Therapeutic Drug Monitoring, 2002, 22(3): 283-294. DOI: https://doi.org/10.1097/00007691-200006000-00009

Griesmacher A., Weigel G., Seebacher G., Müller, M. M.: IMPdehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clinical Chemistry, 1997, 43(12): 2312-2317. DOI: https://doi.org/10.1093/clinchem/43.12.2312

Glander P., Braun K. P., Hambach P., Bauer S., Mai I., Roots I., Budde K.: Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clinical Biochemistry, 2001, 34(7): 543-549. DOI: https://doi.org/10.1016/S0009-9120(01)00267-3

Glander P., Sombogaard F., Budde K., van Gelder T., Hambach P., Liefeldt L., Mathot R. A.: Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Therapeutic Drug Monitoring, 2009, 31(3): 351-359. DOI: https://doi.org/10.1097/FTD.0b013e31819c3f3d

Daxecker H., Raab M., Müller M. M.: Influence of mycophenolic acid on inosine 5′-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells. Clinica Chimica Acta, 2002, 318(1-2): 71-77. DOI: https://doi.org/10.1016/S0009-8981(01)00801-4

Laverdiere I., Caron P., Couture F., Guillemette C., Lévesque E.: Liquid chromatography–coupled tandem mass spectrometry-based assay to evaluate inosine-5′-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients. Analytical Chemistry, 2012, 84(1): 216-223. DOI: https://doi.org/10.1021/ac202404y

Beringer A., Citterio-Quentin A., Otero R. O., Gustin C., Clarke R., Salvi J. P., Boulieu R.: Determination of inosine 5′-monophosphate dehydrogenase activity in red blood cells of thiopurine-treated patients using HPLC. Journal of Chromatography B, 2017, 1044: 194-199. DOI: https://doi.org/10.1016/j.jchromb.2017.01.006

Kawanishi M., Yano I., Yoshimura K., Yamamoto T., Hashi S., Masuda S., Matsubara, K.: Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and

pharmacodynamics in hematopoietic stem cell transplant patients. Biomedical Chromatography, 2015, 29(9): 1309-1316. DOI: https://doi.org/10.1002/bmc.3423

Liu F., Xu L., Sheng C., Qiu X., Zhang M., Jiao, Z.: Optimization and application of an HPLC method for quantification of inosine-5′-monophosphate dehydrogenase activity as a

pharmacodynamic biomarker of mycophenolic acid in Chinese renal transplant patients. Clinica Chimica Acta, 2018, 485: 333-339. DOI: https://doi.org/10.1016/j.cca.2018.06.042

Weißbarth G., Wiesen M. H., Fietz C., Streichert T., Ehren R., Weber L. T., Müller C.: Pharmacodynamic monitoring of Mycophenolic acid therapy: improved liquid chromatography-tandem mass spectrometry method for measuring inosin-5'-monophosphate dehydrogenase activity. Therapeutic Drug Monitoring, 2020, 42(2): 282-288. DOI: https://doi.org/10.1097/FTD.0000000000000688

Spector, T.: Refinement of the Coomassie blue method of protein quantitation: a simple and linear spectrophotometric assay for ≤ 0.5 to 50 μg of protein. Analytical Biochemistry, 1978, 86(1): 42-146. DOI: https://doi.org/10.1016/0003-2697(78)90327-5

Sombogaard F., Peeters A. M., Baan C. C., Mathot R. A., Quaedackers M. E., Vulto A. G., van Gelder T.: Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Therapeutic Drug Monitoring, 2009, 31(5:): 549-556. DOI: https://doi.org/10.1097/FTD.0b013e3181b7a9d0

Brunet M., Shipkova M., van Gelder T., Wieland E., Sommerer C., Budde K., Haufroid V., Christians U., López-Hoyos M., Barten M., Bergan S., Picard N., Millán L., Marquet P., Hesselink D., Noceti O., Pawinski T., Wallemacq P., Oellerich, M.: Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation, Therapeutic Drug Monitoring, 2016, 38(2): 1-20. DOI: https://doi.org/10.1097/FTD.0000000000000287

Arkadiusz Kocur

arkadiusz.kocur@wum.edu.pl

Affiliation:

Zakład Chemii Leków, Wydział Farmaceutyczny, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Dorota Marszałek

Affiliation:

Zakład Chemii Leków, Wydział Farmaceutyczny, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Tomasz Pawiński

Affiliation:

Zakład Chemii Leków, Wydział Farmaceutyczny, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland